GlassScriptPhysician profile
Michael P Smith
NPI 1417939265
$1,027.96
in general payments reported to CMS, 2019-2025
21 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $332 · 2023: $194 · 2024: $120 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $267.03 | 2022-2025 | Atricure Cryoice Cryoablation System (Cryo2), Atriclip Laa Exclusion System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.21 | 2021-2022 | |
| Abiomed | $81.84 | 2022-2023 | Impella |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.55 | 2024-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $63.29 | 2023-2024 | Sapien 3 Ultra Resilia |
| Grifols USA, LLC | $57.82 | 2021-2022 | |
| Abbvie INC. | $48.81 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $48.31 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $41.18 | 2021 | |
| Lilly USA, LLC | $34.41 | 2023-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $27.57 | 2021-2025 | |
| Glaxosmithkline, LLC. | $25.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $23.34 | 2023 | Rexulti |
| Mylan Specialty L.P. | $22.90 | 2021 | |
| Nabriva Therapeutics, Plc | $20.58 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.81 | 2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $17.12 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.15 | 2025 | Kristalose |
| Pfizer INC. | $15.87 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2023 | Eliquis |
| Spr Therapeutics, INC | $10.33 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.